Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project ; volume:8 ; number:12 ; day:23 ; month:11 ; year:2018 ; pages:1-7 ; date:12.2018
Blood cancer journal ; 8, Heft 12 (23.11.2018), 1-7, 12.2018
- Creator
-
Usmani, Saad Z.
Hoering, Antje
Cavo, Michele
Miguel, Jesus San
Goldschmidt, Hartmut
Hajek, Roman
Turesson, Ingemar
Lahuerta, Juan Jose
Attal, Michel
Barlogie, Bart
Lee, Jae Hoon
Kumar, Shaji
Lenhoff, Stig
Morgan, Gareth
Rajkumar, S. Vincent
Durie, Brian G. M.
Moreau, Philippe
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-018-0155-7
- URN
-
urn:nbn:de:101:1-2019010922253357158622
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Usmani, Saad Z.
- Hoering, Antje
- Cavo, Michele
- Miguel, Jesus San
- Goldschmidt, Hartmut
- Hajek, Roman
- Turesson, Ingemar
- Lahuerta, Juan Jose
- Attal, Michel
- Barlogie, Bart
- Lee, Jae Hoon
- Kumar, Shaji
- Lenhoff, Stig
- Morgan, Gareth
- Rajkumar, S. Vincent
- Durie, Brian G. M.
- Moreau, Philippe
- SpringerLink (Online service)
Other Objects (12)
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma